Back to catalog

CJC-1295 / Ipamorelin Astral research vial

CJC-1295 / Ipamorelin

Also known as Mod GRF 1-29 + Ipamorelin (No DAC)

GH-axis research blend — A combination engineered to enhance GH release through synchronized GHRH and ghrelin-receptor activation in experimental research models.

Purity specification: 99%+Lyophilized powder

Available vial sizes

5/5 mg$57.99Out of stock

From $57.99Out of stock

View purchase options

Specifications

CAS number	863288-34-0 / 170851-70-4
Molecular formula	Blend
Molecular weight	3367.97 + 711.85 g/mol
Form	Lyophilized powder

Research use only. Not for human or veterinary use, consumption, diagnosis, treatment, or therapeutic purposes.

Documentation

Certificates of Analysis

Batch-specific, third-party lab certificates. Each COA is published here once its lot has been tested — preview the results, then open the full PDF.

No released lot-specific certificates are currently published for this compound. A certificate appears only after its batch clears release and the source PDF is available.

View the compound COA record →

Related

More to explore

Research context

CJC-1295 / Ipamorelin research, identity and references

Also known as Mod GRF 1-29 + Ipamorelin (No DAC)

What literature relates to the CJC-1295 / Ipamorelin blend?

The blend combines two distinct research compounds. References are separated by constituent because studies of either constituent are not evidence for the combined commercial preparation.

CAS number863288-34-0 / 170851-70-4

Molecular formulaBlend

Molecular weight3367.97 + 711.85 g/mol

SequenceCJC-1295 No-DAC (Mod GRF 1-29) + Ipamorelin

Human pharmacology study

Human pharmacology study
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL, Neale A, Lawrence B, et al. Journal of Clinical Endocrinology & Metabolism (2006).
Characterizes CJC-1295 as a GHRH analog; it does not evaluate Astral's blend.
PMID 16352683 · DOI 10.1210/jc.2005-1536

Preclinical pharmacology study

Preclinical pharmacology study
Ipamorelin, the first selective growth hormone secretagogue.
Raun K, Hansen BS, Johansen NL, et al. European Journal of Endocrinology (1998).
Characterizes ipamorelin receptor activity and selectivity; it does not evaluate the blend.
PMID 9849822 · DOI 10.1530/eje.0.1390552

Animal study

Animal study
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.
Andersen NB, Malmlof K, Johansen PB, et al. Growth Hormone & IGF Research (2001).
An adult-rat bone-formation model for one constituent. A single-constituent animal study is not evidence about a combination.
PMID 11735244 · DOI 10.1054/ghir.2001.0239

Analytical-method study

Analytical-method study
An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
Timms M, Ganio K, Forbes G, et al. Drug Testing and Analysis (2019).
Concerns detection of the analog class. Identity and detection are the questions analytical records answer.
PMID 30489688 · DOI 10.1002/dta.2554

Editorially curated and source-verified; not independently peer-reviewed by Astral. Last source check: 2026-08-04. How sources are selected.

Check released lot evidence →